Septal Occluder Cleared for Use in Very Young Patients

 

February 20, 2008

W. L. Gore & Associates (Gore) announced that the FDA granted approval for the use of GORE HELEX Septal Occluder with a modified catheter delivery system indicated for the transcatheter closure of atrial septal defect (ASD), providing a percutaneous ASD closure solution for very young patients.

The GORE HELEX Septal Occluder is a permanently implanted prosthesis that uses ePTFE, a biocompatible material that allows tissue ingrowth, to seal the defect.

The content of this field is kept private and will not be shown publicly.
Type the characters you see in this picture. (verify using audio)
Type the characters you see in the picture above; if you can't read them, submit the form and a new image will be generated. Not case sensitive.